CNBC interview with Galapagos CEO Onno van de Stolpe

Not for release, publication or distribution in or into the United States, Canada, Australia, Japan or any other jurisdiction where this is not allowed pursuant to local legal restrictions
Dear Biotech investor,
May I please have your attention for the following:
Please click one of these links to watch the CNBC interview with Galapagos CEO Onno van de Stolpe.
With Windows Media Player:
With Real Player:
IPO Biotech company Galapagos in Brussels and Amsterdam
Biotech company Galapagos NV (Mechelen, Belgium and Leiden, The Netherlands) plans to raise up to 40.25 mln eur in an initial public offering on the Brussels and Amsterdam stock exchanges. Subscription for the shares, which are expected to sell for 8-10 eur each, runs up until April 28, 16.00 CET. KBC Securities and Kempen & Co are joint lead managers and bookrunners. The offering includes 35 mln eur in new shares plus 82,562 shares from the exercise of warrants, as well as an over-allotment option of new shares worth another 5.25 mln eur.
About Galapagos
Galapagos is a genomics-based drug discovery company that has successfully discovered and validated novel targets in the bone and joint diseases – osteoarthritis, osteoporosis and rheumatoid arthritis, as well as in asthma and Alzheimer’s disease. Proprietary targets and compounds resulting from these programs are used for Galapagos’ internal discovery programs, combined with selected out-licensing and partnering of projects during development. Galadeno, Galapagos’ services unit, provides reagents and functional screens to leading pharmaceutical, biotech and nutraceutical companies for rapid identification and validation of novel drug targets.
Galapagos currently employs 66 people, including 16 PhDs, and occupies facilities in Mechelen, Belgium, and Leiden, The Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene, GSK, Vertex and Wyeth.
Galapagos was founded in 1999 by Crucell (Nasdaq, Euronext: CRXL) and Tibotec (now an affiliate of J&J) to exploit Crucell’s unique PER.C6® technology for target discovery. The shareholders include Abingworth Management, AlpInvest Partners, Apax Partners, Burrill & Company, Crucell and Tibotec-Virco.
For more information please visit the Galapagos website:
The prospectus can be downloaded from the IPO information section on the website.
Or contact Kempen & Co. in Amsterdam or KBC in Brussels
Kind regards,
Galapagos NV
Onno van de Stolpe, CEO
Mobile phone: +31 6 290 98 028
For more information about Galapagos, please contact:
Galapagos nv
Industriepark Mechelen Noord
Generaal De Wittelaan L11 A3
B-2800 Mechelen, Belgium
Tel: +32 15 34 29 00
Fax: +32 15 34 29 01